Table 1 Best systemic and CNS response rates among patients with active CNS lymphoma.
Variable | (CNS + systemic) | CNSa | ||
|---|---|---|---|---|
ORR, n (%) | CR, n (%) | ORR, n (%) | CR, n (%) | |
All patients, n = 18a | 10 (56%) | 6 (33%) | 11 (65%) | 6 (35%) |
Bispecific agent | ||||
▪ Glofitamab, n = 15a | 9 (60%) | 5 (33%) | 10 (71%) | 5 (36%) |
▪ Epcoritamab, n = 2 | 1 (50%) | 1 (50%) | 1 (50%) | 1 (50%) |
▪ Mosunetuzumab, n = 1 | 0 | 0 | 0 | 0 |
CNS site | ||||
▪ Parenchymal, n = 12 | 8 (67%) | 5 (42%) | 9 (75%) | 5 (42%) |
▪ Leptomeningeal, n = 3 | 2 (67%) | 1 (33%) | 2 (67%) | 1 (33%) |
▪ Both, n = 3a | 0 | 0 | 0 | 0 |
Treatment type | ||||
▪ Monotherapy, n = 6a | 4 (67%) | 3 (50%) | 4 (80%) | 3 (60%) |
▪ Combination, n = 12 | 6 (50%) | 3 (25%) | 7 (58%) | 3 (33%) |
Lymphoma histology | ||||
▪ DLBCL, n = 13a | 8 (62%) | 5 (38%) | 9 (75%) | 5 (42%) |
▪ HGBL, n = 2 | 0 | 0 | 0 | 0 |
▪ PCNSL, n = 2 | 1 (50%) | 1 (50%) | 1 (50%) | 1 (50%) |
▪ MCL, n = 1 | 1 (100%) | 0 | 1 (100%) | 0 |
Prior CAR T-cell therapy | ||||
▪ Yes, n = 11 | 7 (64%) | 4 (36%) | 8 (73%) | 4 (36%) |
▪ No, n = 7a | 3 (43%) | 2 (29%) | 3 (50%) | 2 (33%) |
Time from CART to bispecific | ||||
▪ ≤6 months, n = 4 | 2 (50%) | 2 (50%) | 2 (50%) | 2 (50%) |
▪ >6 months, n = 7 | 5 (71%) | 2 (29%) | 6 (86%) | 2 (29%) |
Time from first CNS involvement to bispecific | ||||
▪ ≤6 months, n = 8a | 5 (63%) | 3 (38%) | 5 (71%) | 3 (43%) |
▪ >6 months, n = 10 | 5 (50%) | 3 (30%) | 6 (60%) | 3 (30%) |
Prior lines of treatment | ||||
▪ 2, n = 9a | 6 (67%) | 4 (44%) | 6 (75%) | 4 (50%) |
▪ ≥3, n = 9 | 4 (44%) | 2 (22%) | 5 (56%) | 2 (22%) |
